TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study in Nature Medicine links lower levels of the protective protein NRF2 in oligodendrocytes to abnormal myelin and loss of large nerve fibers in older adults with faster cognitive decline. Mouse experiments support a possible causal role, but the findings do not show that an NRF2-targeting drug can prevent age-related decline in people.
Researchers studying older adults and mice found that oligodendrocytes—brain cells that make and maintain nerve-fiber insulation—may become dysfunctional with age and contribute to cognitive decline. The study, published in Nature Medicine, links lower levels of the protective protein NRF2 in those cells with abnormal myelin and damage to large nerve fibers, and points to a pathway that could be investigated for future treatments.
The team, led by researchers from the University of Edinburgh and the UK Dementia Research Institute, examined data from the Lothian Birth Cohort 1936. Participants had cognitive abilities tracked from childhood into older age. Between ages 70 and 82, researchers assessed memory, information-processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional testing after age 70; most experienced some decline, though its rate differed.
In brain tissue collected after death from a subset of participants, greater decline was associated with fewer large nerve fibers and an abnormal buildup of myelin, the fatty coating that helps electrical signals travel along nerve fibers. The tissue findings were associated with the rate of cognitive change, not simply how well participants performed at one particular age. They do not, on their own, establish that myelin changes caused the decline.
The researchers also found that people with more severe decline had lower NRF2 levels in oligodendrocytes. In mice, experimentally reducing NRF2 in those cells led to excessive myelin, loss of large nerve fibers and less improvement in cognitive performance as the animals aged. These experiments support a possible causal link in mice, but they do not prove the same mechanism causes cognitive decline in humans.
A New Target in Brain Aging
The findings challenge the assumption that oligodendrocytes are uniformly protective. They suggest that changes in the cells responsible for maintaining myelin could be part of the process associated with age-related loss of memory and thinking skills. That may broaden research beyond nerve cells themselves to the support cells that help them function.
The NRF2 pathway offers a potential lead because medications that act on it are already used for other neurological conditions, including multiple sclerosis. The study authors raise the possibility that existing drugs could inform future research. However, the study did not test an NRF2-targeting treatment in older adults, and it does not establish that such medication would preserve cognition or be appropriate for that purpose.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The Lothian Birth Cohort gives researchers an unusually long view of cognitive change: participants’ abilities were measured from childhood and followed into later life. Repeated testing allows scientists to distinguish the pace of decline from a single score taken in old age. Researchers used post-mortem tissue from some cohort members to look for brain features associated with those differing trajectories.
The study combined that human evidence with experiments in mice. The human analysis identifies associations between cognitive change, myelin abnormalities and NRF2 levels; the mouse work tested what happened when NRF2 was reduced in oligodendrocytes. The approaches answer different questions: one links brain features to changes in people, while the other provides experimental evidence about a mechanism in animals.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital, part of Unity Health Toronto
As an affiliate, we earn on qualifying purchases.
Human Treatment Benefits Remain Unknown
The human tissue findings show an association, not proof that reduced NRF2 activity or abnormal myelin caused participants’ cognitive decline. The mouse experiments strengthen the case for a mechanism but cannot establish that it works the same way in people. The report does not provide evidence that raising NRF2 levels would reverse existing damage or prevent decline in older adults.
It also remains unclear which patients, if any, might benefit from treatments acting on this pathway, what dose or timing might be needed, and what risks could arise. A drug used for multiple sclerosis cannot be assumed to be safe or effective for age-related cognitive decline without dedicated clinical testing.
cognitive decline support supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing the Pathway in People
The next step is further research to establish how NRF2 activity changes in oligodendrocytes during human aging and whether that change predicts later cognitive outcomes. Researchers would also need to test whether treatments that affect the pathway can safely improve or preserve cognition in older adults.
Any move toward clinical use would require trials designed for age-related cognitive decline, with appropriate measures of benefit and safety. The study identifies a possible direction for that work, but the source report does not specify a trial schedule or say that a clinical study in older adults is underway.
neuroprotective brain health products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are oligodendrocytes?
Oligodendrocytes are brain cells that produce and maintain myelin, the coating around nerve fibers that helps electrical signals travel efficiently.
What did the study find in people?
In a subset of Lothian Birth Cohort participants whose brain tissue was examined after death, faster cognitive decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes. These are associations and do not establish cause in people.
Did the researchers test a treatment for cognitive decline?
No. The study identified the NRF2 pathway as a possible research target, but did not test an NRF2-targeting drug in older adults with cognitive decline.
Why were mice included in the research?
Researchers reduced NRF2 specifically in mouse oligodendrocytes to investigate whether this could produce brain changes similar to those seen in human tissue. The mice developed excess myelin, lost large nerve fibers and showed less improvement in cognitive performance as they aged.
No. The report notes that drugs acting on NRF2 are used for other conditions, including multiple sclerosis, but whether such a treatment would help older adults with cognitive decline has not been established.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
